Journal
Blood Advances
Publication Date
6-10-2025
Volume
9
Issue
11
First Page
2663
Last Page
2676
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2024013656
Rights and Permissions
Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, Lin Y, Lunning MA, Hill BT, Ghobadi A, Hu ZH, Hemmer MT, Zoratti MJ, Vunnum S, Tsang J, Spooner C, Smith H, Fu C, Patel A, Miao H, Shahani SA, Mirjah DL, Xu H, Pasquini MC. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 2025 Jun 10;9(11):2663-2676. doi: 10.1182/bloodadvances.2024013656. © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Locke, Frederick L; Ghobadi, Armin; and et al., "Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel." Blood Advances. 9, 11. 2663 - 2676. (2025).
https://digitalcommons.wustl.edu/oa_4/5900
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
